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Dear Editor,
We are writing to comment on the paper “Association 
between the use of aspirin and risk of lung cancer: results 
from pooled cohorts and Mendelian randomization analy-
ses” by Jiang et al. (Jiang et al. 2020). Findings from this 
Mendelian randomization (MR) study suggest that aspirin 
use decreases the incidence of lung cancer, specifically over-
all lung cancer and squamous cell carcinoma.
Observational studies have provided some evidence for 
the use of aspirin as a chemopreventive agent in lung can-
cer (relative risk 0.93, 95%CI 0.87–1.00) (Qiao et al 2018). 
However, few randomized trials have been carried out to 
answer this question. Using genetic variation as a method 
of randomization to aspirin use and testing for association 
with specific cancers within an MR framework is, therefore, 
an attractive method to appraise causality before long and 
costly trials are conducted.
The authors used genetic variants from a genome-wide 
association study (GWAS) on aspirin use conducted by the 
Neale Lab (UK Biobank—Neale lab) to test whether aspirin 
intake was causally related to lung cancer incidence. How-
ever, there are some potential concerns with this method of 
instrumenting aspirin use.
One of the first major concerns with using instruments 
from a GWAS of drug use is disentangling the genetic 
variants for the drug from those for the drug’s indication. 
Using the MRC IEU OpenGWAS database (Elsworth et al. 
2020), we found that the SNPs that predict aspirin use by 
this study (rs583104, rs2521501, rs10455872, rs73015016, 
rs7412, rs1831733, rs117733303) have all been shown to be 
associated with coronary artery disease (CAD) risk at least 
at genome-wide significance (van der Harst and Verweij 
2018; Nikpay et al. 2015). Therefore, it may be that these 
SNPs increase the risk of CAD and that these individuals are 
being instructed to take aspirin as a preventative measure, 
thereby confounding the SNP association with aspirin use.
Many of the SNPs used to instrument aspirin use are also 
associated with a large number of other risk factors in the 
MRC IEU OpenGWAS database (Elsworth et al. 2020). 
This raises the potential for the violation of two of the 
MR assumptions: no confounding (independence assump-
tion) and no horizontal pleiotropy (exclusion restriction 
assumption). Specifically, SNPs rs583104, rs10455872, 
rs73015016, rs7412 and rs117733303 have previously been 
associated with levels of low-density lipoprotein (LDL) cho-
lesterol at genome-wide significance (Global Lipids Genet-
ics Consortium, 2013; Prins et al. 2017), with increasing 
LDL-cholesterol levels leading to increased risk of coro-
nary heart disease (Richardson et al. 2020). If cardiovascular 
risk factors are causally related to lung cancer incidence, as 
suggested by a previous MR study where increasing LDL-
cholesterol levels was inversely associated with lung cancer 
incidence (OR 0.90, 95% CI 0.84–0.97 per SD of 38 mg/
dl) (Carreras-Torres et al. 2017), then this may introduce 
confounding into the MR analysis.
Alternatively, associations between the genetic variants 
being used to instrument aspirin use and other risk factors 
could indicate violation of the exclusion restriction assump-
tion of MR—namely, that the SNP is only affecting the out-
come via the exposure of interest (Lawlor et al. 2008). When 
SNPs are also associated with other risk factors that may 
affect disease risk, this is termed horizontal pleiotropy (Bur-
gess and Thompson 2013); however, we do acknowledge 
that the MR Egger regression was conducted and found little 
evidence of pleiotropy (Bowden et al. 2015). Furthermore, 
a weighted median approach was carried out and consistent 
results with the IVW were observed for overall lung cancer 
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(OR 1.32 × 10–4, 95% CI 1.69 × 10–7 to 0.10, P value: 0.05) 
indicating a similar causal effect even if 50% of the weight 
came from invalid instruments (Bowden et al. 2015).
Another threat to the validity of findings is the poten-
tial for selection bias. Since many of the SNPs may also 
be proxying liability to CAD, this may indicate survival 
bias, whereby individuals with higher risk of CAD die 
prematurely and, therefore, do not live long enough to be 
diagnosed with lung cancer. A frailty analysis could be con-
ducted in this case to re-estimate the causal estimate in the 
presence of survival bias (Noyce et al. 2017).
A final concern with the results presented are the very 
large effect sizes (overall lung cancer, OR 0.042, 95% CI 
0.003–0.564 and squamous cell lung cancer, OR 0.002, 95% 
CI 1.21 × 10–5 to 0.301) obtained from the MR analysis, 
which are much larger in magnitude than the corresponding 
observational estimates presented in the study (overall lung 
cancer relative risk (RR): 0.95, 95% CI 0.91–0.98, P value: 
0.004; and squamous cell lung cancer RR: 0.80, 95% CI: 
0.65 to 0.98, P value: 0.034). While it is possible for MR 
to estimate larger causal effects than corresponding obser-
vational analyses; for example, in the presence of negative 
confounding or short-term exposure, a more detailed assess-
ment of the genetic estimates used in the analysis is first 
required. In particular, the GWAS for aspirin use conducted 
by the Neale lab was conducted on the absolute risk differ-
ence rather than log-odds scale and, therefore, the MR effect 
estimates presented are unlikely to be directly comparable to 
those obtained in the accompanying observational analysis.
Using the same SNPs and datasets, we first replicated 
the results to confirm that the same exposure and out-
come datasets were being used before transforming the 
SNP–exposure associations to a more interpretable scale 
for binary traits (the log odds scale) using the formula 
provided by Elsworth et  al. (2019) and re-conducting 
the MR analysis (code to reproduce the analysis in this 
paper: https ://githu b.com/an043 5/aspir in_lung_cance 
r_MR/). The transformed MR results can be interpreted 
as the OR for lung cancer per doubling of aspirin use. 
After conversion, a doubling of aspirin use decreases the 
risk of lung cancer and squamous cell lung cancer by 31% 
and 52%, respectively (lung cancer IVW OR 0.69, 95% 
CI 0.51–0.94 and squamous cell lung cancer IVW OR 
0.48, 95% CI 0.27–0.87) (Table 1). Using the numbers 
of cases and sample sizes from the cohort studies listed 
in the paper, the prevalence of lung cancer was 0.51% 
(72,782/14,369,951*100). When the disease is rare in a 
population such as with lung cancer (prevalence below 
10%), the OR can be interpreted as a relative risk, making 
the results from the observational analysis and MR com-
parable (Sedgwick, 2014). These transformed MR results 
and their confidence intervals now partially overlap with 
the observational estimates. (overall lung cancer observa-
tional RR: 0.95, 95% CI 0.91–0.98, MR OR 0.69, 95% CI: 
0.51–0.94; squamous cell lung cancer observational RR: 
0.80, 95% CI 0.65–0.98, MR OR 0.48, 95% CI 0.27–0.87).
One alternative approach to study drug effects using 
MR is to identify SNPs that mimic a drug’s mechanism of 
action by investigating SNPs in the genes of the targeted 
protein (Gill et al. 2019). For example, statins inhibit the 
enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A reduc-
tase (HMGCR) resulting in reduced levels of LDL-choles-
terol (Ference et al. 2015). Based on this understanding, 
SNPs that are in or around (within 100 kb) the HMGCR 
gene and that are associated with LDL-cholesterol have 
proven a useful method to instrument exposure to statins 
in MR studies (Ference et al. 2015, 2016). In the case of 
drugs such as aspirin that have multiple targets, it may be 
useful to conduct proteomic analysis to identify proteins 
targeted by the drug and instrument the effect of changes 
in mRNA/protein levels on cancer risk (Nounu et  al. 
2020). Instrumenting levels of mRNA/protein expression 
provides a continuous exposure, compared to aspirin use 
which is a binary variable and, therefore, results in com-
plications when conducting and interpreting MR analyses 
(Burgess and Labrecque 2018).
Whilst we acknowledge that conducting MR studies of 
drug use and cancer incidence would provide much needed 
answers for clinical intervention, careful consideration in 
MR study design is needed when instrumenting drug use 
in MR to avoid the potential pitfalls highlighted. Methods 
and guidelines are now available for informing best prac-
tice in MR (Burgess et al. 2020; Davey Smith et al. 2019) 
so that appropriate inference can be made.
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Table 1  MR results using exposure instruments transformed to the log odds scale
IVW Weighted median MR Egger
OR LCI UCI P value OR LCI UCI P value OR LCI UCI P value
Lung cancer 0.69 0.51 0.94 0.02 0.60 0.42 0.87 0.01 0.36 0.16 0.77 0.05
Lung adenocarcinoma 0.71 0.38 1.33 0.29 0.55 0.31 0.98 0.04 0.38 0.06 2.22 0.33
Squamous cell lung cancer 0.48 0.27 0.87 0.02 0.50 0.27 0.93 0.03 0.36 0.06 2.03 0.30
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